文献速递消化道肿瘤与早癌

抑制EHMT2诱导半乳糖凝集素-7增强微卫星稳定结直肠癌的免疫

Galectin-7 Induction by EHMT2 Inhibition Enhances Immunity in Microsatellite Stability Colorectal Cancer.
PubMed 文献 · Gastroenterology · 2023-12-06

本研究通过体外CRISPR筛选,在微卫星稳定(MSS)结直肠癌患者原发肿瘤细胞与自体免疫细胞共培养模型中,发现组蛋白甲基转移酶EHMT2为潜在靶点。抑制EHMT2可改变细胞因子表达,将免疫抑制微环境转为免疫调节性,激活T细胞介导的细胞毒性并改善对抗PD1治疗的应答。抑制EHMT2后半乳糖凝集素-7上调,将「冷」肿瘤环境转为T细胞浸润型;给予半乳糖凝集素-7可增强抗PD1疗效。

要点

  • 体外CRISPR筛选发现EHMT2是MSS结直肠癌的潜在免疫治疗靶点。
  • 抑制EHMT2通过改变细胞因子表达激活T细胞毒性并改善抗PD1应答。
  • 半乳糖凝集素-7上调可将「冷」MSS肿瘤转为T细胞浸润型并增强抗PD1疗效。

核心结论

  • 靶向EHMT2/半乳糖凝集素-7轴可能为MSS结直肠癌免疫治疗提供新的联合策略。

研究设计与样本

  • 采用MSS结直肠癌患者原发肿瘤细胞与自体免疫细胞共培养模型进行体外CRISPR筛选,以识别可增强MSS肿瘤免疫治疗疗效的表观遗传靶点。

主要发现

  • 抑制EHMT2通过改变细胞因子表达,将MSS肿瘤的免疫抑制微环境转变为免疫调节性微环境,激活T细胞介导的细胞毒性并改善对抗PD1治疗的应答。
  • 抑制EHMT2后观察到半乳糖凝集素-7上调,将「冷」MSS肿瘤环境转变为T细胞浸润型。
  • 机制上,CHD4通过招募EHMT2形成共转录沉默复合物来抑制半乳糖凝集素-7表达。
  • 给予半乳糖凝集素-7可增强抗PD1在MSS结直肠癌中的疗效,作为有效的辅助细胞因子治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although immunotherapy shows substantial advancement in colorectal cancer (CRC) with microsatellite instability high, it has limited efficacy for CRC with microsatellite stability (MSS). Identifying combinations that reverse immune suppression and prime MSS tumors for current immunotherapy approaches remains an urgent need. METHODS: An in vitro CRISPR screen was performed using coculture models of primary tumor cells and autologous immune cells from MSS CRC patients to identify epigenetic targets that could enhance immunotherapy efficacy in MSS tumors. RESULTS: We revealed EHMT2, a histone methyltransferase, as a potential target for MSS CRC. EHMT2 inhibition transformed the immunosuppressive microenvironment of MSS tumors into an immunomodulatory one by altering cytokine expression, leading to T-cell-mediated cytotoxicity activation and improved responsiveness to anti-PD1 treatment. We observed galectin-7 up-regulation upon EHMT2 inhibition, which converted a "cold" MSS tumor environment into a T-cell-inflamed one. Mechanistically, CHD4 repressed galectin-7 expression by recruiting EHMT2 to form a cotranscriptional silencing complex. Galectin-7 administration enhanced anti-PD1 efficacy in MSS CRC, serving as a potent adjunct cytokine therapy. CONCLUSIONS: Our findings suggest that targeting the EHMT2/galectin-7 axis could provide a novel combination strategy for immunotherapy in MSS CRC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Sun L, Liu R, Wu ZJ, et al. Galectin-7 Induction by EHMT2 Inhibition Enhances Immunity in Microsatellite Stability Colorectal Cancer. Gastroenterology. 2023. PMID: 38065340. doi:10.1053/j.gastro.2023.11.294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。